Skip to main content

Table 4 Combined primary and secondary outcome measures selected and reported in pediatric EoE trials

From: Systematic review of outcome measures in pediatric eosinophilic esophagitis treatment trials

 

Konikoff [18]

Schaeffer [19]

Dohil [20]

Assa’ad [21]

Spergel [22]

Gupta [23]

Page [25]

NCT01458418

Di Nardo [26]

NCT01846962

Teva Pharm [27]

NCT00635089

McGuire Davis [28]

NCT01821898

Heine [24]

ACTRN12613001210763

Esophageal eosinophilia or histologic remission (eosinophils/HPF)

X

 

X

X

X

X

X

  

X

X

Histologic features

X

  

X

 

X

     

Histology scoring tool

  

X

        

Severity score for endoscopy and histology

       

X

   

Biopsy grade

 

X

         

Endoscopic features

X

  

X

       

Modified endoscopy tool

  

X

       

X

Compound histologic and symptom response

     

X

     

Clinical symptoms

X

          

“Clinical response” (combined patient report and physician assessment)

 

X

         

Clinical severity score

       

X

   

Symptom scoring tool

  

X

       

X

EoE clinical symptom score

     

X

     

Pediatric EoE symptom severity module

         

X

 

Predominant symptom assessment scores (patient report)

    

X

      

Physician global assessment score

    

X

      

PedsQL

         

X

 

CHQ scores

    

X

      

Tolerability

   

X

       

Pharmacokinetics

   

X

       

Genotypic features

  

X

        

Blood eosinophil counts

   

X

       

Proteonomic features

      

X

  

X

X

Immune features

         

X

X

Profile of durability of response to treatment

        

X

  

Safety or adverse events

   

X

X

X

  

X